Torsade de pointes: The clinical considerations

International Journal of Cardiology

Volumn 96, Issue 1, 2004, Pages 1-6

  Gowda, Ramesh M ^a   Khan, Ijaz A ^b,c   Wilbur, Sabrina L ^a   Vasavada, Balendu C ^a   Sacchi, Terrence J ^a  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Long QT syndrome; Sudden arrhythmia death syndrome; Sudden cardiac death; Torsade de pointes; Ventricular tachycardia

Indexed keywords

AMIODARONE; AMPICILLIN; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; ATROPINE; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; BRETYLIUM; CLARITHROMYCIN; DISOPYRAMIDE; DIURETIC AGENT; ERYTHROMYCIN; FLECAINIDE; ISOPRENALINE; LEVOFLOXACIN; LIDOCAINE; MAGNESIUM SULFATE; MEXILETINE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PHENYTOIN; POTASSIUM CHANNEL; PROCAINAMIDE; SODIUM CHANNEL; UNINDEXED DRUG;

CLINICAL TRIAL; ELECTROCARDIOGRAPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SINUS NODE; SURFACE PROPERTY; TORSADE DES POINTES;

ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; RISK FACTORS; TORSADES DE POINTES;

EID: 2942527155     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.04.055     Document Type: Review

References (55)

1. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Arch. Mal. Coeur. 59:1966;263-272
2. Leenhardt A., Glaser E., Burguera M., Nurnberg M., Maison-Blanche P., Coumel P. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 89:1994;206-215
3. Nguyen P.T., Scheinman M.M., Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy and QT interval. Circulation. 74:1986;340-349
4. Kay G.N., Plumb V.J., Arciniegas J.G., Henthorn R.W., Waldo A.L. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J. Am. Coll. Cardiol. 2:1983;806-817
5. Gomes J.A., Alexopoulos D., Winters S.L., Deshmukh P., Fuster V., Suh K. The role of silent ischemia, the arrhythmic substrate and the short-long sequence in the genesis of sudden cardiac death. J. Am. Coll. Cardiol. 14:1989;1618-1625
6. Steinbrecher U.P., Fitchett D.H. Torsade de pointes: a cause of syncope with atrioventricular block. Arch. Intern. Med. 140:1980;1223-1226
7. Vincent G.M. The molecular basis of the long QT syndrome: genes causing fainting and sudden death. Annu. Rev. Med. 49:1998;263-274
8. Zareba W., Moss A.J., le Cessie S., et al. Risk of cardiac events in family members of patients with long QT syndrome. J. Am. Coll. Cardiol. 26:1995;1685-1691
9. El-Sherif N., Craelius W., Boutjdir M., Gough W.B. Early afterdepolarizations and arrhythmogenesis. J. Cardiovasc. Electrophysiol. 1:1990;145-160
10. El-Sherif N., Caref E.B., Yin H., Restivo M. The electrophysiological mechanism of ventricular tachyarrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ. Res. 79:1996;474-492
11. Ebert S.N., Liu X.K., Woosley R.L. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J. Womens Health. 7:1998;547-557
12. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., Lehmann M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 270:1993;2590-2597
13. Bednar M.M., Harrigan E.P., Ruskin J.N. Torsades de pointes associated with non-antiarrhythmic drugs and observations on gender and QTc. Am. J. Cardiol. 89:2002;1316-1319
14. Roden D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin. Electrophysiol. 21:1998;1029-1034
15. Ponti F.D., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the qt interval or induce torsade de pointes: an overview. Drug Saf. 25:2002;263-286
16. Haverkamp W., Breithardt G., Camm A.J., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur. Heart J. 21:2000;1216-1231
17. Surawicz B., Knoebel S.B. Long QT: good, bad and indifferent. J. Am. Coll. Cardiol. 4:1984;398-413
18. Zareba W., Moss A.J., le Cessie S., Hall W.J. T wave alternans in idiopathic long QT syndrome. J. Am. Coll. Cardiol. 23:1994;1541-1546
19. Soroker D., Ezri T., Szmuk P., Merlis P., Epstein M., Caspi A. Perioperative torsade de pointes ventricular tachycardia induced by hypocalcemia and hypokalemia. Anesth. Analg. 80:1995;630-633
20. Khan I.A. Mechanisms of syncope and Stokes-Adams attacks in bradyarrhythmias: asystole and torsade de pointes. Cardiology. 2002;98
21. Ludomirsky A., Klein H.O., Sarelli P., et al. QT prolongation and polymorphous (torsades de pointes) ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am. J. Cardiol. 49:1982;1654-1658
22. Di Pasquale G., Pinelli G., Andreoli A., Manini G.L., Grazi P., Tognetti F. Torsade de pointes and ventricular flutter-fibrillation following spontaneous cerebral subarachnoid hemorrhage. Int. J. Cardiol. 18:1988;163-172
23. Vourc'h G., Tannieres M.L. Cardiac arrhythmia induced by pneumoencephalography. Br. J. Anaesth. 50:1978;833-839
24. Kearney P., Reardon M., O'Hare J. Primary hyperparathyroidism presenting as torsades de pointes. Br. Heart J. 70:1993;473
25. Fredlund B.O., Olsson S.B. Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism. Acta Med. Scand. 213:1983;231
26. Singh B.N., Gaarder T.D., Kanegae T., Goldstein M., Montgomerie J.Z., Mills H. Liquid protein diets and torsade de pointes. JAMA. 240:1978;115-119
27. Wolf G.L., Hirshfeld J.W. Jr. Changes in QTc interval induced with Renografin-76 and Hypaque-76 during coronary arteriography. J. Am. Coll. Cardiol. 11:1983;1489-1492
28. Shimizu K., Miura Y., Meguro Y., et al. QT prolongation with torsade de pointes in pheochromocytoma. Am. Heart J. 124:1992;235-239
29. Salle P., Rey J.L., Bernasconi P., Quiret J.C., Lombaert M. Torsade de pointes: a propos of 60 cases. Ann. Cardiol. Angeiol. (Paris). 34:1985;381-388
30. Grenadier E., Alpan G., Maor N., et al. Polymorphous ventricular tachycardia in acute myocardial infarction. Am. J. Cardiol. 53:1984;1280-1283
31. Chiche P., Haiat R., Steff P. Angina pectoris with syncope due to paroxysmal atrioventricular block: role of ischemia: report of two cases. Br. Heart J. 36:1974;577-581
32. Krikler D.M., Curry P.V. Torsade de pointes: an atypical ventricular tachycardia. Br. Heart J. 38:1976;117-120
33. Horowitz L.N., Greenspan A.M., Spielman S.R., Josephson M.E. Torsade de pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities. Circulation. 63:1981;1120-1128
34. Kocheril A.G., Bokhari S.A., Batsford W.P., Sinusas A.J. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin. Electrophysiol. 20:1997;2810-2816
35. Villa A., Foresti V., Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin. Auton. Res. 5:1995;48-52
36. Singh N., Singh H.K., Singh P.P., Khan I.A. Cocaine-induced torsades de pointes in idiopathic long-QT syndrome. Am. J. Ther. 8:2001;299-302
37. Khan I.A., Win M.T., Bali A.J., Vasavada B.C., Sacchi T.J. Torsade de pointes: a case with multiple variables. Am. J. Emerg. Med. 17:1999;80-85
38. Zareba W., Moss A.J., Schwartz P.J., et al. Influence of genotype on the clinical course of the long-QT syndrome: International Long-QT Syndrome Registry Research Group. N. Engl. J. Med. 339:1998;960-965
39. Locati E.H., Zareba W., Moss A.J., et al. Age-and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 97:1998;2237-2244
40. Zareba W., Moss A.J. Long QT syndrome in children. J. Electrocardiol. 34(S):2001;167-171
41. Vincent G.M., Timothy K., Leppert M., Keating M. The spectrum of symptoms and QT interval in carriers of the gene for the long QT syndrome. N. Engl. J. Med. 327:1992;846-852
42. Khan I.A. Clinical and therapeutic aspects of congenital and acquired long-QT syndrome. Am. J. Med. 112:2002;58-66
43. Khan I.A. Twelve-lead electrocardiogram of torsade de pointes. Tex. Heart Inst. J. 28:2001;69
44. Khan I.A. Long-QT syndrome: diagnosis and management. Am. Heart J. 143:2002;7-14
45. Tzivoni D., Banai S., Schuger C. Treatment of torsades de pointes with magnesium sulfate. Circulation. 77:1988;392
46. Monraba R., Sala C. Percutaneous overdrive pacing in the out-of-hospital treatment of torsades de pointes. Ann. Emerg. Med. 33:1999;356-357
47. Magnano A.R., Holleran S., Ramakrishnan R., Reiffel J.A., Bloomfield D.M. Autonomic nervous system influences on QT interval in normal subjects. J. Am. Coll. Cardiol. 39:2002;1820-1826
48. Choy A.M., Lang C.C., Chomsky D.M., Rayos G.H., Wilson J.R., Roden D.M. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 96:1997;2149-2154
49. Noda T., Takaki H., Kurita T., et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur. Heart J. 23:2002;975-983
50. Dorostkar P.C., Eldar M., Belhassen B., Scheinman M.M. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 100:1999;2431-2436
51. Groh W.J., Silka M.J., Oliver R.P., et al. Use of implantable cardioverter defibrillators in the congenital long QT syndrome. Am. J. Cardiol. 78:1996;703-706
52. Compton S.J., Lux R.L., Ramsey M.R., et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation. 94:1996;1018-1022
53. Shimizu W., Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsades de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 102:2000;706-712
54. Schwartz P., Priori S., Locati E., et al. Long QT syndrome patients with mutations of the SCN- and HERG genes have differential responses to Na channel blockade and to increases in heart rate. Circulation. 92:1995;3381-3386
55. Benhorin J., Taub R., Goldmit M., et al. Effects of flecainide in patients with new SCN-mutation: mutation specific therapy for long-QT syndrome? Circulation. 101:2000;1698-1706